Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss

Nord J Psychiatry. 2005;59(3):205-8. doi: 10.1080/08039480510027689.


In this pilot study, we have investigated the effects of switching from olanzapine or risperidone treatment to low-dose perphenazine combined with buspirone in six schizophrenic patients who had experienced weight gain. We found no relapse as to psychotic symptoms measured by the CGI-S scale and no exacerbation of extrapyramidal side-effects as measured by the Simpson-Angus Scale. In addition, we observed a medium weight reduction of 10.5 kg (range 1-20 kg).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Basal Ganglia Diseases / chemically induced*
  • Benzodiazepines / therapeutic use
  • Buspirone / therapeutic use*
  • Denmark
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Olanzapine
  • Perphenazine / therapeutic use*
  • Pilot Projects
  • Risperidone / therapeutic use*
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Serotonin Receptor Agonists / therapeutic use*
  • Weight Loss / drug effects*


  • Antipsychotic Agents
  • Serotonin Receptor Agonists
  • Benzodiazepines
  • Perphenazine
  • Risperidone
  • Olanzapine
  • Buspirone